Abstract
MicroRNAs (miRNAs) are a class of small (18~25 nucleotides long) non-coding RNAs that regulate gene expression on the post-transcriptional level. During the last decade, the field of miRNA research has been exponentially expanding, revealing the widespread role of these molecules in numerous biological processes. Aberrant miRNA expression has been documented in multiple haematologic malignancies, including B cell lymphomas. There is compelling evidence that miRNAs can function as oncogenes or tumor suppressor genes in lymphoid malignancies. In this review, we recapitulate the current knowledge of miRNA expression in B cell malignancies and discuss the accumulating evidence for a major role of miRNA deregulation in the development of B cell-derived lymphoid tumors.
Keywords: B cells, Hodgkin lymphoma, leukemia, lymphoma, MicroRNA.
Current Molecular Medicine
Title:Role of MicroRNAs in B Cell Leukemias and Lymphomas
Volume: 14 Issue: 5
Author(s): A. Schmidt and R. Kuppers
Affiliation:
Keywords: B cells, Hodgkin lymphoma, leukemia, lymphoma, MicroRNA.
Abstract: MicroRNAs (miRNAs) are a class of small (18~25 nucleotides long) non-coding RNAs that regulate gene expression on the post-transcriptional level. During the last decade, the field of miRNA research has been exponentially expanding, revealing the widespread role of these molecules in numerous biological processes. Aberrant miRNA expression has been documented in multiple haematologic malignancies, including B cell lymphomas. There is compelling evidence that miRNAs can function as oncogenes or tumor suppressor genes in lymphoid malignancies. In this review, we recapitulate the current knowledge of miRNA expression in B cell malignancies and discuss the accumulating evidence for a major role of miRNA deregulation in the development of B cell-derived lymphoid tumors.
Export Options
About this article
Cite this article as:
Schmidt A. and Kuppers R., Role of MicroRNAs in B Cell Leukemias and Lymphomas, Current Molecular Medicine 2014; 14 (5) . https://dx.doi.org/10.2174/1566524014666140603095414
DOI https://dx.doi.org/10.2174/1566524014666140603095414 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targets for Anti-metastatic Drug Development
Current Pharmaceutical Design Overview of Proteasome Inhibitor-Based Anti-cancer Therapies: Perspective on Bortezomib and Second Generation Proteasome Inhibitors versus Future Generation Inhibitors of Ubiquitin-Proteasome System
Current Cancer Drug Targets PRAME/EZH2-Mediated Regulation of TRAIL: A New Target for Cancer Therapy
Current Molecular Medicine Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Review of the Third Domain Receptor Binding Fragment of Alphafetoprotein (AFP): Plausible Binding of AFP to Lysophospholipid Receptor Targets
Current Drug Targets Lycopene: A Review of Its Potential as an Anticancer Agent
Current Medicinal Chemistry - Anti-Cancer Agents Editorial [Hot Topic: Why Apoptosis in Pediatric Disorders?]
Current Pediatric Reviews Inhibitory Effect of Fruit Juices on the Doxorubicin Metabolizing Activity of Carbonyl Reductase 1
Drug Metabolism Letters Molecular Kinetics and Targeting Within the Nucleus
Current Chemical Biology Challenges and Advances in Infection Control of Hematopoietic Stem Cell Transplant Recipients
Infectious Disorders - Drug Targets All in the Family: The TNF-TNFR Superfamily in the Pathogenesis and Treatment of Rheumatoid Arthritis and other Inflammatory Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Natural Products as Anti-Cancerous Therapeutic Molecules Targeted towards Topoisomerases
Current Protein & Peptide Science Identification of Disease-Relevant Genes for Molecularly-Targeted Drug Discovery
Current Cancer Drug Targets Depsipeptide (FK228) as a Novel Histone Deacetylase Inhibitor: Mechanism of Action and Anticancer Activity
Mini-Reviews in Medicinal Chemistry Platelet Ca2+ATPases: Identification and Regulation in Hypertension
Current Hypertension Reviews Small Molecule Inhibitors of NF-κB and JAK/STAT Signal Transduction Pathways as Promising Anti-Inflammatory Therapeutics
Mini-Reviews in Medicinal Chemistry The PKB/AKT Pathway in Cancer
Current Pharmaceutical Design Editorial (Thematic Issue: Clonal Heterogeneity and Diversification in B-cell Disorders)
Current Cancer Therapy Reviews Reconstituted High Density Lipoprotein-Based Nanoparticles: an Overview of Applications in Regenerative Medicine, Preparation, Evaluation and Future Trends
Current Pharmaceutical Design False Positive of <sup>68</sup>Ga-DOTATATE PET-CT in a Paraganglioma
Endocrine, Metabolic & Immune Disorders - Drug Targets